These data not only indicate the effect of CK2 inhibitors on the promotion of Ikaros function, but also suggest that Ikaros-induced changes in expression of the BCL6/BACH2 axis are at least partially responsible for the application of CK2 inhibitors in B-ALL therapy. This evidence concerns the gene BCL6 and acute lymphoblastic leukemia.